Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Isotron licenses ORNL cancer treatment technology

24.11.2004


Patients with cancers previously next to untreatable may have new hope because of a license agreement between Isotron of Norcross, Ga., and UT-Battelle, which manages Oak Ridge National Laboratory.



The license allows Isotron to market a treatment called neutron brachytherapy, which enables physicians to deliver a highly concentrated dose of californium-252 neutrons to the site of a tumor instead of having to treat the tumor with conventional gamma rays, which often are not as effective at killing cancer cells. The benefit to patients should be tremendous.

"This new procedure could be used to more effectively treat literally thousands of patients with cancer, including brain tumors, some of which today have five-year survival rates of less than 1 percent," said Manfred Sandler, a cardiologist and chief executive officer of Isotron. "So we see this as an extremely significant development in the race to cure cancer."


Sandler hopes the treatment, which will allow physicians to treat nearly 20 types of cancer, is available by early 2007. Cancers most resistant to conventional treatments include brain tumors, melanoma, sarcoma, certain types of prostate cancer, locally advanced breast cancer, cervical cancer and cancer of the head, neck and mouth.

The key to the new treatment is the miniaturization of the californium-252 source, which allows physicians to insert the radioisotope through a catheter directly to the tumor site. Researchers at Isotron and in ORNL’s Nuclear Science & Technology Division reduced the diameter of the source -- the wire that contains the radioisotope -- by more than half from the previous standard of about 2.8 millimeters. The length has also been significantly reduced. Although the dimensions are much smaller, the strength of the source is significantly higher. This makes it possible to reach and treat tumors that previously could be treated only with conventional photon and gamma brachytherapy or with external beam treatments. In addition, because of the potency of the source, treatment times will be significantly reduced.

Another significant technological challenge involved development of a method for making the source capsules that are attached to the wire that allows for the insertion of the radioisotope. Isotron’s method combines the radioisotope source with a remote automated storage and delivery system that uses the latest imaging, surgical and patient treatment planning techniques.

The licensing agreement, signed earlier this month, is the culmination of a three-year cooperative research and development agreement funded entirely by Isotron. The license grants Isotron rights to two patents detailing how to make miniature californium-252 sources for neutron brachytherapy and how to attach them to small-diameter wires. The work was performed in ORNL’s Californium User Facility.

"This is a perfect example of how collaborations between ORNL and the private sector can result in technology to make our lives better," said Alex Fischer, director of ORNL’s Office of Technology Transfer and Economic Development. "Through this work with Isotron, thousands of people can perhaps be cured of cancer and go on to lead normal lives."

Sandler envisions the treatment being useful for treating many of some 260,000 combined cases of prostate cancer, cervical cancer, brain tumors and melanomas.

ORNL, which is managed by UT-Battelle, employs 1,500 scientists and engineers and is the Department of Energy’s largest multipurpose science and energy laboratory.

Ron Walli | EurekAlert!
Further information:
http://www.ornl.gov

More articles from Health and Medicine:

nachricht GLUT5 fluorescent probe fingerprints cancer cells
20.04.2018 | Michigan Technological University

nachricht Scientists re-create brain neurons to study obesity and personalize treatment
20.04.2018 | Cedars-Sinai Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Spider silk key to new bone-fixing composite

University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.

Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.

Im Focus: Writing and deleting magnets with lasers

Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...

Im Focus: Gamma-ray flashes from plasma filaments

Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.

The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...

Im Focus: Basel researchers succeed in cultivating cartilage from stem cells

Stable joint cartilage can be produced from adult stem cells originating from bone marrow. This is made possible by inducing specific molecular processes occurring during embryonic cartilage formation, as researchers from the University and University Hospital of Basel report in the scientific journal PNAS.

Certain mesenchymal stem/stromal cells from the bone marrow of adults are considered extremely promising for skeletal tissue regeneration. These adult stem...

Im Focus: Like a wedge in a hinge

Researchers lay groundwork to tailor drugs for new targets in cancer therapy

In the fight against cancer, scientists are developing new drugs to hit tumor cells at so far unused weak points. Such a “sore spot” is the protein complex...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

IWOLIA: A conference bringing together German Industrie 4.0 and French Industrie du Futur

09.04.2018 | Event News

 
Latest News

Magnetic nano-imaging on a table top

20.04.2018 | Physics and Astronomy

Start of work for the world's largest electric truck

20.04.2018 | Interdisciplinary Research

Atoms may hum a tune from grand cosmic symphony

20.04.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>